TY - JOUR T1 - Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers JF - bioRxiv DO - 10.1101/2021.03.05.434089 SP - 2021.03.05.434089 AU - Stéphane Marot AU - Isabelle Malet AU - Aude Jary AU - Valentin Leducq AU - Basma Abdi AU - Elisa Teyssou AU - Cathia Soulie AU - Marc Wirden AU - Christophe Rodriguez AU - Slim Fourati AU - Jean-Michel Pawlotsky AU - David Boutolleau AU - Sonia Burrel AU - Vincent Calvez AU - Anne-Geneviève Marcelin Y1 - 2021/01/01 UR - http://biorxiv.org/content/early/2021/03/05/2021.03.05.434089.abstract N2 - There are concerns about neutralizing antibodies (NAb) potency against the newly emerged VOC202012/01 (UK) and 501Y.V2 (SA) SARS-CoV-2 variants in mRNA-vaccinated subjects and in recovered COVID-19 patients. We used a viral neutralization test with a strict 100% neutralizing criterion on UK and SA clinical isolates in comparison with a globally distributed D614G SARS-CoV-2 strain. In two doses BNT162b2-vaccinated healthcare workers (HCW), despite heterogeneity in neutralizing capacity against the three SARS-CoV-2 strains, most of the sera harbored at least a NAb titer ≥ 1:10 suggesting a certain humoral protection activity either on UK or SA variants. However, six months after mild forms of COVID-19, an important proportion of HCW displayed no neutralizing activity against SA strain. This result supports strong recommendations for vaccination of previously infected subjects.Competing Interest StatementThe authors have declared no competing interest. ER -